Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Malin buys 33% interest in UK’s Wren Therapeutics
Founded in 2016, Wren was spun out of the University of Cambridge and Lund University, Sweden. It is engaged in the drug discovery and development for protein misfolding diseases,
Founded in 2016, Wren was spun out of the University of Cambridge and Lund University, Sweden. It is engaged in the drug discovery and development for protein misfolding diseases,
The SMC approved the use of Elbasvir-grazoprevir, known as Zepatier, saying it is a combination of two medicines that inhibit the replication of the Hepatitis C virus and
Baricitinib is being co-developed by Eli Lilly and Company and Incyte under an exclusive global license and collaboration agreement signed in December 2009. It is intended to be taken orally
The improvement was observed in the 4mg/day dose arm, while the 2mg/day dose arm did not show a statistically significant difference from placebo. Both dasotraline arms were generally
The QIDP status provides for accelerated review of the New Drug Application (NDA) as well as a five-year period of market exclusivity for the indication, if approved. Currently,
The US Court of Appeals for the Federal Circuit has upheld the earlier district court's decision that a proposed generic equivalent from Teva Pharmaceutical Industries would infringe on
Merck paid $230m upfront for two clinical-stage DNA damage and repair candidates and two additional preclinical programs, of which the company will take full responsibility in development and commercialization. US-based
The US Food and Drug Administration (FDA) has accepted Mylan’s biologics license application (BLA) for the biosimilar, MYL-1401O, for review through the 351 (k) pathway. The expected FDA
The therapeutic compound was studied for its safety and tolerability and was found to have stabilized the disease on CT imaging in a majority of patients in the
L’Oreal will pay Valeant $1.3bn for three skin-care brands, CeraVe, AcneFree and AMBI. The CeraVe, AcneFree, and AMBI product lines have annualized revenue of about $168m. Founded in